Cargando…
Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization
Cancer neoantigens that arise from somatic mutations have emerged as important targets for personalized immunization. Here, we report an improved overall survival of a HER2-positive metastatic breast cancer patient using a bioinformatic-based personalized peptide immunization called BITAP (BioInform...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301538/ https://www.ncbi.nlm.nih.gov/pubmed/37376412 http://dx.doi.org/10.3390/vaccines11061023 |
_version_ | 1785064835346595840 |
---|---|
author | Schönharting, Wolfgang Roehnisch, Tim Manoochehri, Mehdi Christoph, Jan Sieger, Marie Nogueira, Mauro Martos-Contreras, Mari Carmen Kunz, Meik |
author_facet | Schönharting, Wolfgang Roehnisch, Tim Manoochehri, Mehdi Christoph, Jan Sieger, Marie Nogueira, Mauro Martos-Contreras, Mari Carmen Kunz, Meik |
author_sort | Schönharting, Wolfgang |
collection | PubMed |
description | Cancer neoantigens that arise from somatic mutations have emerged as important targets for personalized immunization. Here, we report an improved overall survival of a HER2-positive metastatic breast cancer patient using a bioinformatic-based personalized peptide immunization called BITAP (BioInformatic Tumor Address Peptides). The epitopes were predicted using our in-house bioinformatic pipeline, and the immunogenicity was tested by IFN-γ ELISPOT and intracellular cytokine staining assays. In total, a significant peptide-specific T-cell response was detected against 18 out of the 76 (≈24%) tested peptides. The patient’s follow-up by measuring serologic markers showed a significant reduction in the tumor marker levels following BITAP immunization. Along with standard treatment, the patient treated with the BITAP showed stable disease with a remarkably improved overall survival, and no serious treatment-related adverse effects. In conclusion, our findings suggest that BITAP immunization is feasible, and safe, and may induce tumor regressions in patients with HER2-positive subsets of breast cancer. |
format | Online Article Text |
id | pubmed-10301538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103015382023-06-29 Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization Schönharting, Wolfgang Roehnisch, Tim Manoochehri, Mehdi Christoph, Jan Sieger, Marie Nogueira, Mauro Martos-Contreras, Mari Carmen Kunz, Meik Vaccines (Basel) Case Report Cancer neoantigens that arise from somatic mutations have emerged as important targets for personalized immunization. Here, we report an improved overall survival of a HER2-positive metastatic breast cancer patient using a bioinformatic-based personalized peptide immunization called BITAP (BioInformatic Tumor Address Peptides). The epitopes were predicted using our in-house bioinformatic pipeline, and the immunogenicity was tested by IFN-γ ELISPOT and intracellular cytokine staining assays. In total, a significant peptide-specific T-cell response was detected against 18 out of the 76 (≈24%) tested peptides. The patient’s follow-up by measuring serologic markers showed a significant reduction in the tumor marker levels following BITAP immunization. Along with standard treatment, the patient treated with the BITAP showed stable disease with a remarkably improved overall survival, and no serious treatment-related adverse effects. In conclusion, our findings suggest that BITAP immunization is feasible, and safe, and may induce tumor regressions in patients with HER2-positive subsets of breast cancer. MDPI 2023-05-25 /pmc/articles/PMC10301538/ /pubmed/37376412 http://dx.doi.org/10.3390/vaccines11061023 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Schönharting, Wolfgang Roehnisch, Tim Manoochehri, Mehdi Christoph, Jan Sieger, Marie Nogueira, Mauro Martos-Contreras, Mari Carmen Kunz, Meik Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization |
title | Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization |
title_full | Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization |
title_fullStr | Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization |
title_full_unstemmed | Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization |
title_short | Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization |
title_sort | improved survival of a her2-positive metastatic breast cancer patient following a personalized peptide immunization |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301538/ https://www.ncbi.nlm.nih.gov/pubmed/37376412 http://dx.doi.org/10.3390/vaccines11061023 |
work_keys_str_mv | AT schonhartingwolfgang improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization AT roehnischtim improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization AT manoochehrimehdi improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization AT christophjan improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization AT siegermarie improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization AT nogueiramauro improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization AT martoscontrerasmaricarmen improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization AT kunzmeik improvedsurvivalofaher2positivemetastaticbreastcancerpatientfollowingapersonalizedpeptideimmunization |